Investigators examined use of tapentadol, which has µ-opioid receptor agonist and norepinephrine reuptake inhibitor activity, for moderate-to-severe chronic osteoarthritis knee pain or low back pain.
There were no significant differences between tapentadol ER and a placebo or oxycodone CR in changes from baseline to endpoint in blood pressure or heart rate.
Read the Clinical Advisor on pain.
Related Articles on Analgesics for Pain Management:
Dr. Bruce Nicholson Presents Four Strategies to Tackle Post-Op Pain
Study: Certain Analgesia Decreases Phantom Limb Pain
Drug Response Profile Dependent on Pain Mechanism and Opioid Type
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.